1. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Issue 11 (November 2022) Authors: Mallory, Raburn M; Formica, Neil; Pfeiffer, Susan; Wilkinson, Bethanie; Marcheschi, Alex; Albert, Gary; McFall, Heather; Robinson, Michelle; Plested, Joyce S; Zhu, Mingzhu; Cloney-Clark, Shane; Zhou, Bin; Chau, Gordon; Robertson, Andreana; Maciejewski, Sonia; Hammond, Holly L; Baracco, Lauren; Lo... Journal: Lancet infectious diseases Issue: Volume 22:Issue 11(2022) Page Start: 1565 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, Tolerability, and Pharmacokinetics of IMU‐935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double‐Blind, Placebo‐Controlled, First‐in‐Human Phase 1 Study. Issue 5 (20th March 2023) Authors: Polasek, Thomas M.; Leelasena, Indika; Betscheider, Irina; Marolt, Marija; Kohlhof, Hella; Vitt, Daniel; Fliegert, Frank; Muehler, Andreas R. Journal: Clinical pharmacology in drug development Issue: Volume 12:Issue 5(2023) Page Start: 525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗